TY - JOUR
T1 - Efficacy of mepolizumab in usual clinical practice and characteristics of responders
T2 - Mepolizumab in usual clinical practice
AU - Rodríguez-García, Carlota
AU - Blanco-Aparicio, Marina
AU - Nieto-Fontarigo, Juan José
AU - Blanco-Cid, Nagore
AU - Gonzalez-Fernandez, Coral
AU - Mosteiro-Añon, Mar
AU - Calvo-Alvarez, Uxío
AU - Perez-De-Llano, Luis
AU - Corbacho-Abelaira, María Dolores
AU - Lourido-Cebreiro, Tamara
AU - Dominguez-Juncal, Luis Miguel
AU - Crespo-Diz, Carlos
AU - Dacal-Quintas, Raquel
AU - Pallares-Sanmartin, Abel
AU - Dacal-Rivas, David
AU - Gonzalez-Barcala, Francisco Javier
PY - 2021
Y1 - 2021
N2 - Background: Severe eosinophilic asthma is a high-burden disease. Mepolizumab has been effective in several randomized clinical trials. However, such success might not be applicable to patients treated in usual clinical practice. The objectives of this article are to evaluate the efficacy of mepolizumab in severe uncontrolled eosinophilic asthma under usual clinical practice, and to determine characteristics associated with the response to this treatment. Methods: We have conducted a retrospective, multicentre study, including all adult patients with severe uncontrolled eosinophilic asthma in Galicia, Spain, on whom mepolizumab treatment was started before June 2020, at least 6 months before the time of inclusion, and had received at least one dose of the drug. Patient characteristics, clinical data, respiratory function and comorbidities were collected at baseline and at the 6-month-follow-up. Responders and super-responders were defined according to clinical response and requirement of systemic corticosteroids. Results: 122 patients (mean age 58 years old) were included. In the follow-up treatment 6 months later, 75.4% of the patients were well-controlled, displaying a significant reduction in blood eosinophil counts (p < 0.001), hospital admissions and disease exacerbations (p < 0.001), and had their systemic glucocorticosteroid dose significantly reduced (p < 0.001). The inhaled corticosteroid dose was also lowered (p < 0.01) after 6 months of treatment. Around two-thirds had a clinically significant increase in FEV1, 95% of the patients were considered responders and 43% super-responders. Conclusion: In routine clinical practice, mepolizumab is effective in patients with severe eosinophilic asthma and it has a good safety profile.
AB - Background: Severe eosinophilic asthma is a high-burden disease. Mepolizumab has been effective in several randomized clinical trials. However, such success might not be applicable to patients treated in usual clinical practice. The objectives of this article are to evaluate the efficacy of mepolizumab in severe uncontrolled eosinophilic asthma under usual clinical practice, and to determine characteristics associated with the response to this treatment. Methods: We have conducted a retrospective, multicentre study, including all adult patients with severe uncontrolled eosinophilic asthma in Galicia, Spain, on whom mepolizumab treatment was started before June 2020, at least 6 months before the time of inclusion, and had received at least one dose of the drug. Patient characteristics, clinical data, respiratory function and comorbidities were collected at baseline and at the 6-month-follow-up. Responders and super-responders were defined according to clinical response and requirement of systemic corticosteroids. Results: 122 patients (mean age 58 years old) were included. In the follow-up treatment 6 months later, 75.4% of the patients were well-controlled, displaying a significant reduction in blood eosinophil counts (p < 0.001), hospital admissions and disease exacerbations (p < 0.001), and had their systemic glucocorticosteroid dose significantly reduced (p < 0.001). The inhaled corticosteroid dose was also lowered (p < 0.01) after 6 months of treatment. Around two-thirds had a clinically significant increase in FEV1, 95% of the patients were considered responders and 43% super-responders. Conclusion: In routine clinical practice, mepolizumab is effective in patients with severe eosinophilic asthma and it has a good safety profile.
KW - Asthma
KW - Eosinophils
KW - Interleukin-5
KW - Mepolizumab
KW - Monoclonal antibodies
KW - Precision medicine
U2 - 10.1016/j.rmed.2021.106595
DO - 10.1016/j.rmed.2021.106595
M3 - Article
C2 - 34492540
AN - SCOPUS:85114193198
SN - 0954-6111
VL - 187
JO - Respiratory Medicine
JF - Respiratory Medicine
M1 - 106595
ER -